

# Raji/Human PD-L1 Stable Cell Line Development Service Data Sheet

## Raji/Human PD-L1 Stable Cell Line


Catalog No.	Size
SCRAJ-STT075	2 × (1 vial contains ~5×10 <sup>6</sup> cells)

### • Description

The Raji/Human PD-L1 Stable Cell Line was engineered to express full length human PD-L1 (Gene ID: 29126, used to mimic cancer target cells. When co-cultured with human PD-1 Reporter Cell, the PD-1/PD-L1 interaction inhibits TCR signaling and NFAT-mediated luminescence. Blocking the PD-1/PD-L1 interaction by either anti-PD-1 or anti-PD-L1 antibodies releases the inhibitory signal and results in TCR activation and NFAT-mediated luminescence.

### • Application

- Useful for cell-based PD-L1 binding assay
- Useful as PD-L1-expressing target cells in reporter gene assay



### • Cell Line Profile

Cell line	Raji/Human PD-L1 Stable Cell Line
Host Cell	Raji
Property	Suspension
Complete Growth Medium	RPMI-1640 + 10% FBS
Selection Marker	Puromycin (2 µg/mL)
Incubation	37°C with 5% CO <sub>2</sub>
Doubling Time	16-20 hours
Transduction Technique	Lentivirus

## Raji/Human PD-L1 Stable Cell Line Development Service Data Sheet

### • *Materials Required for Cell Culture*

- RPMI-1640 (ATCC, Cat.No.30-2001)
- Fetal bovine serum (Gibco, Cat.No.10091-148)
- Puromycin (InvivoGen, Cat.No.ant-pr-5b)
- Complete Growth Medium: RPMI-1640 + 10% FBS
- Culture Medium: RPMI-1640 + 10% FBS, Puromycin (2 µg/mL)
- Freeze Medium: 90% FBS, 10% (V/V) DMSO
- T-75 Culture flask (Corning, 430641)
- Cryogenic storage vials (SARSTEDT, 72.379.007)
- Thermostat water bath
- Centrifuge
- Luna cell counter (Logos Biosystems, LUNA- II )
- CO<sub>2</sub> Incubator (Thermo, 3111)
- Biological Safety Cabinet (Thermo, 1389)

### • *Recovery*

1. Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the cap out of the water. Thawing should be rapid (approximately 5 minutes).
2. Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by spraying with 70% ethanol. All the operations from this point on should be carried out under strict aseptic conditions.
3. Transfer the vial contents to a centrifuge tube containing 4.0 mL complete growth medium.
4. Count viable cells and spin at approximately 1000 rpm for 5 minutes.
5. Discard the supernatant and resuspend the cell pellet in an appropriate amount of fresh complete growth medium. Adjust the cell density of the suspension to  $1 \times 10^6$  viable cells/mL and transfer cells to an appropriate size vessel.
6. Incubate at 37°C with 5% CO<sub>2</sub> incubator

## Raji/Human PD-L1 Stable Cell Line Development Service Data Sheet

### • *Subculture*

Adjust the cell density at  $1 \times 10^5$ - $2 \times 10^5$  viable cells/mL by the addition of fresh medium or replacement of culture medium. Do not allow the cell density to exceed  $2 \times 10^6$  cells/mL. T-75 flasks are recommended for subculturing.

- **Medium Renewal:** Add fresh culture medium every 3 to 4 days (depending on cell density)

### • *Cryopreservation*


1. Count viable cells and harvest the cell suspension.
2. Centrifuge at 1000 rpm for 5 min at RT and resuspend cells in freezing medium to a concentration of  $5 \times 10^6$  to  $1 \times 10^7$  cells/mL.
3. Aliquot into cryogenic storage vials. Place vials in a programmable cooler or an insulated box placed in a  $-80^\circ\text{C}$  freezer overnight, then transferring to liquid nitrogen storage.

### • *Storage*

- **Product format:** Frozen
- **Storage conditions:** Liquid nitrogen immediately upon receipt


# Raji/Human PD-L1 Stable Cell Line Development Service Data Sheet

• *Receptor Assay*



**Fig1. Expression analysis of human PD-L1 on Raji/Human PD-L1 Stable Cell by FACS.** Raji/Human PD-L1 Stable Cell Line or negative control cell were stained with PE-labeled anti-human PD-L1 antibody.


• *Application*



**Fig2. Blocking activity of anti-human PD-1 antibody (RLU).** This Raji/Human PD-L1 Stable Cell Line was incubated with serial dilutions of antibodies in the presence of reporter cells expressing human PD-1. The EC50 of anti-human PD-1 antibody was approximately 1.189 µg/mL.


# Raji/Human PD-L1 Stable Cell Line Development Service Data Sheet

## Anti-human PD-1 Antibody Screening (FOLD)



**Fig3. Blocking activity of anti-human PD-1 antibody (FOLD).** This Raji/Human PD-L1 Stable Cell Line was incubated with serial dilutions of antibodies in the presence of reporter cells expressing human PD-1. The max induction fold was approximately 22.47.

### • Passage Stability



Passage	MFI for PD-L1 (PE)
P13	28433
P17	28102
P20	33895
P29	34902

**Fig4. Passage stability analysis of receptors expression by FACS.** Flow cytometry surface staining of human PD-L1 on Raji/Human PD-L1 Stable Cell Line demonstrates consistent mean fluorescent intensity across across passage 13-29.

# Raji/Human PD-L1 Stable Cell Line Development Service Data Sheet

• ***License Disclosure***

This reporter cell is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this reporter cell available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this reporter cell in any way. Inappropriate use or distribution of this reporter cell will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this reporter cell for any particular use, and does not accept any liability in connection with the handling or use of this reporter cell.

• ***Related Products***

**Products**

Raji/Human CD155 Stable Cell Line

**Cat.No.**

SCRAJ-STT076